Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 8. 8- Aryloxymethyl- and 8-arylthiomethyldipyridodiazepinones

Journal of Medicinal Chemistry

Volumn 41, Issue 16, 1998, Pages 2972-2984

  Cywin, Charles L ^a   Klunder, Janice M ^a   Hoermann, MaryAnn ^a   Brickwood, Janice R ^a   David, Eva ^a   Grob, Peter M ^a   Schwartz, Racheline ^a   Pauletti, Daniel ^a   Barringer, Kevin J ^a   Shih, Cheng Kon ^a   Sorge, Christopher L ^a   Erickson, David A ^a   Joseph, David P ^a   Hattox, Susan E ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5,11 DIHYDRO 11 ETHYL 5 METHYL 8 (PHENYLTHIO)METHYL 6H DIPYRIDO[3,2 B:2',3' E][1,4]DIAZEPIN 6 ONE; 2 CHLORO 5,11 DIHYDRO 11 ETHYL 5 METHYL 8 [2 (PYRIDIN 4 YL)ETHYL] 6H DIPYRIDO[3,2 B:2',3' E][1,4]DIAZEPIN 6 ONE; 2 CHLORO 5,11 DIHYDRO 11 ETHYL 5 METHYL 8 PHENYLETHYL 6H DIPYRIDO[3,2 B:2',3' E][1,4]DIAZEPIN 6 ONE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DIPYRIDODIAZEPINONE DERIVATIVE; MUTANT PROTEIN; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG METABOLISM; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INTRAVENOUS DRUG ADMINISTRATION; LIVER METABOLISM; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT;

ANIMALS; ANTIVIRAL AGENTS; AZEPINES; BIOLOGICAL AVAILABILITY; CELL LINE, TRANSFORMED; CELL SURVIVAL; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, MICROBIAL; DRUG STABILITY; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MICROSOMES, LIVER; MUTATION; NEVIRAPINE; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

EID: 15144354770     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9707030     Document Type: Article

References (35)

1. For previous papers in this series, see: (a) Klunder, J. M.; Hoermann, M.; Cywin, C. L.; David, E.; Brickwood, J. R.; Schwartz, R.; Barringer, K. J.; Pauletti, D.; Shih, C.-K.; Erickson, D. A.; Sorge, C. L.; Joseph, D. P.; Hattox, S. E.; Adams, J.; Grob, P. M. Novel Nonnucleoside Inhibitors of HIV-1 Reverse Transcriptase. 7. 8-Arylethyldipyridodiazepinones as Potent Broad-Spectrum Inhibitors of Wild-Type and Mutant Enzymes. J. Med. Chem. 1998, 41, 2960-2971. (b) Kelly, T. A.; McNeil, D. W.; Rose, J. M.; David, E.; Shih, C.-K.; Grob, P. M Novel Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. 6. 2-Indol-3-yl and 2-azaindol-3-yl Dipyridodiazepinones. J. Med. Chem. 1997, 40, 2430-2433.
2. For previous papers in this series, see: (a) Klunder, J. M.; Hoermann, M.; Cywin, C. L.; David, E.; Brickwood, J. R.; Schwartz, R.; Barringer, K. J.; Pauletti, D.; Shih, C.-K.; Erickson, D. A.; Sorge, C. L.; Joseph, D. P.; Hattox, S. E.; Adams, J.; Grob, P. M. Novel Nonnucleoside Inhibitors of HIV-1 Reverse Transcriptase. 7. 8-Arylethyldipyridodiazepinones as Potent Broad-Spectrum Inhibitors of Wild-Type and Mutant Enzymes. J. Med. Chem. 1998, 41, 2960-2971. (b) Kelly, T. A.; McNeil, D. W.; Rose, J. M.; David, E.; Shih, C.-K.; Grob, P. M Novel Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. 6. 2-Indol-3-yl and 2-azaindol-3-yl Dipyridodiazepinones. J. Med. Chem. 1997, 40, 2430-2433.
3. (a) Merluzzi, V. J.; Hargrave, K. D.; Labadia, M.; Grozinger, K.; Skoog, M.; Wu, J. C.; Shih, C.-K.; Eckner, K.; Hattox, S.; Adams, J.; Rosenthal, A. S.; Faanes, R.; Eckner, R. J.; Koup, R. A.; Sullivan, J. L. Inhibition of HIV-1 Replication by a Non-Nucleoside Reverse Transcriptase Inhibitor. Science 1990, 250, 1411-1413.
4. (b) Hargrave, K. D.; Proudfoot, J. R.; Grozinger, K. G.; Kapadia, S. R.; Patel, U. R.; Fuchs, V. U.; Mauldin, S. C.; Vitous, J.; Behnke, M. L.; Klunder, J. M.; Pal, K.; Skiles, J. W.; McNeil, D. W.; Rose, J. M.; Chow, G. C.; Skoog, M. T.; Wu, J. C.; Schmidt, G.; Engel, W.; Eberlein, W. G.; Saboe, T. D.; Campbell, S. J.; Rosenthal, A. S.; Adams, J. Novel Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. 1. Tricyclic Pyridobenzo- and Dipyridodiazepinones. J. Med. Chem. 1991, 34, 2231-2241.
5. (a) Luzuriaga, K.; Bryson, Y.; Krostad, P.; Robinson, J.; Stechenberg, B.; Lamson, M.; Cort, S.; Sullivan J. L. Combination Treatment With Zidovudine, Didanosine, and Nevirapine In Infants With Human Immunodeficiency Virus Type 1 Infection. N. Engl. J. Med. 1997, 336, 1343-1349.
6. (b) D'Aquila, R. T.; Hughes, M. D.;, Johnson, V. A., Fischl, M. A., Sommadossi, J.-P.; Liou, S.; Timpone, J.; Myers, M.; Basgoz, N.; Niu, M.; Hirsch, M. S, and the National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group 241 Investigators. Nevirapine, Zidovudine, and Didanosine Compared With Zidovudine and Didanosine In Patients With HIV-1 Infection. Ann. Int. Med. 1996, 124, 1019-1030.
7. (a) Unpublished results.
8. (b) Sahai, J.; Cameron, W.; Salgo, M.; Stewart. F.; Myers, M.; Lamson, M.; Gagnier, P. Drug Interaction Study between Saquinavir (SQV) and Nevirapine (NVP). The 4th Conference on Retroviruses and Opportunistic Infections; 1997; Abstract 614.
9. (a) Harris, M.; Durakovic, C.; Conway, B.; Fransen, S.; Shillington, A.; Montaner, J. S. G. A Pilot Study of Indinavir, Nevirapine, and 3TC in Patients with Advanced HIV Disease. The 4th Conference on Retroviruses and Opportunistic Infections, 1997; Abstract 234.
10. (b) Murphy, R.; Gagnier, P.; Lamson, M.; Dusek, A.; Ju, W.; Hsu, A. Effect of Nevirapine (NVP) on Pharmacokinetics (PK) of Indinavir (IDV) and Ritonavir (RTV) in HIV-1 Patients. The 4th Conference on Retroviruses and Opportunistic Infections; 1997; Abstract 374.
11. (a) Vella, S.; Franca Pirillo, M. Combination Therapy in the Management of HIV Infection. Methods Find. Exp. Clin. Pharmacol. 1996, 18 (Suppl. C), 23-26.
12. (b) Doran, C. M. New Approaches To Using Antiretroviral Therapy For The Management Of HIV Infection. Ann. Pharmacother. 1997, 31, 228-236.
13. (a) Kohlstaedt, L. A.; Wang, J.; Friedman, J. M.; Rice, P. A.; Steitz, T. A. Crystal Structure at 3.5A Resolution of HIV-1 Reverse Transcriptase Complexed With An Inhibitor. Science 1992, 256, 1783-1790.
14. (b) Smerdon, S. J.; Jager, J.; Wang, J.; Kohlstaedt, L. A.; Friedman, J. M.; Rice, P. A.; Steitz, T. A. Structure Of The Binding Site for Nonnucleoside Inhibitors Of The Reverse Transcriptase Of Human Immunodeficiency Virus Type 1. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 3911-3915.
15. (c) Esnouf, R.; Ren, J.; Ross, C.; Jones, Y.; Stammers, D.; Stuart, D. Mechanism Of Inhibition Of HIV-1 Reverse Transcriptase By Non-Nucleoside Inhibitors. Struct. Biol. 1995, 2, 303-308.
16. (a) Richman, D.; Shih, C.-K.; Lowy, I.; Rose, J.; Prodanovich, P.; Goff, S.; Griffin, J. Human Immunodeficiency Virus Type 1 Mutants Resistant To Nonnucleoside Inhibitors Of Reverse Transcriptase Arise In Tissue Culture. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 11241-11245.
17. (b) Richman, D.; Havlir, D.; Corbeil, J.; Looney, D.; Ignacio, C.; Spector, S. A.; Sullivan, J.; Cheeseman, S.; Barringer, K.; Pauletti, D.; Shih, C.-K.; Myers, M.; Griffin, J. Nevirapine Resistance Mutations Of Human Immunodeficiency Virus Type 1 Selected During Therapy. J. Virol. 1994, 68, 1660-1666.
18. Matsumoto, J.; Miyamoto, T.; Minamida, A.; Nishimura, Y.; Egawa, H.; Nishimura, H. Synthesis of Fluorinated Pyridines by the Balz-Schiemann Reaction. An Alternative Route To Enoxacin, A New Antibacterial Pyridonecarboxylic Acid. J. Heterocycl. Chem. 1984, 21, 673-679.
19. Available from Lancaster Synthesis, Windham, NH.
20. For an alternative approach to related 8-bromo compounds, see: Proudfoot, J. R.; Patel, U. R.; Kapadia, S. R.; Hargrave, K. D. Novel Non-Nulceoside Inhibitors of HIV-1 Reverse Transcriptase. 3. Dipyrido[2,3-b:2′,3′-e]diazepinones. J. Med. Chem. 1995, 38, 1406-1410.
21. Proudfoot, J. R. Unpublished results.
22. (a) Fukuhara, T.; Yoneda, N.; Takamura, K.; Suzuki, A. The Preparation Of p-Fluorophenols from p-Aminophenols: Diazotization And Fluorodediazoniation In Pyridine-HF. J. Fluorine Chem. 1991, 51, 299-304.
23. (b) Fukuhara, T.; Yoneda, N.; Sawada, T.; Suzuki, A. An Improved Procedure for Diazotization Fluoro-Dediazoniation of Anilines Using Base-HF Agents. Synth. Commun. 1987, 17, 685-692.
24. Lane, C. F. Sodium Cyanoborohydride - A Highly Selective Reducing Agent For Organic Functional Groups. Synthesis 1975, 135-146.
25. Data not shown.
26. (a) Powis, G.; Jardine, I.; Van Dyke, R.; Weishilboum, R.; Moore, D.; Wilke, T.; Rhodes, W.; Nelson, R.; Benson, L.; Szumlanski, C. Foreign Compound Metabolism Studies With Human Liver Obtained as Surgical Waste, Relation To Donor Characteristics And Effects Of Tissue Storage. Drug Metab. Dispos. 1988, 16, 582-589.
27. (b) Guengerich, F. P. Analysis and characterization of enzymes. In Principles and Methods of Toxicology, Hayes, A. W., Ed.; Raven Press Ltd.: New York, 1994; pp 1259-1313.
28. (c) Lowry, O. H.; Rosenbrough, N. J.; Farr, A. L.; Randall, R. J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193, 265-275.
29. A description of these assays has appeared in ref 1b.
30. Freimuth, W. W. Delaviridine mesylate, a potent nonnucleoside HIV-1 reverse transcriptase inhibitor. Adv. Exp. Med. Biol. 1996, 394 (Antiviral Chemotherapy 4), 279-289.
31. (a) Chow, Y. K.; Hirsch, M. S.; Merrill, D. P.; Bechtel, L. J.; Eron, J. J.; Kaplan, J. C.; D'Aquila, R. T. Use of Evolutionary Limitations of HIV-1 Multidrug Resistance to Optimize Therapy. Nature 1993, 361, 650-654.
32. (b) Chow, Y. K.; Hirsch, M. S.; Kaplan, J. C.; D'Aquila, R. T. HIV-1 Error Revealed [letter]. Nature 1993, 364, 679.
33. (c) Emini, E. A.; Graham, D. J.; Gotlib, L.; Condra, J. H.; Byrnes, V. W.; Schleif, W. A. HIV and Multidrug Resistance [letter; comment]. Nature 1993, 364, 679.
34. (d) Larder, B. A.; Kellam, P.; Kemp, S. D. Convergent Combination Therapy Can Select Viable Multidrug-Resistant HIV-1 in vitro. Nature 1993, 365, 451-453.
35. Full details of these experiments will be reported in due course.